REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 572 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
REGN had a positive operating cash flow in the past year.
In the past 5 years REGN has always been profitable.
In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
REGN's Return On Assets of 12.43% is amongst the best of the industry. REGN outperforms 96.99% of its industry peers.
With an excellent Return On Equity value of 15.87%, REGN belongs to the best of the industry, outperforming 96.64% of the companies in the same industry.
REGN's Return On Invested Capital of 9.81% is amongst the best of the industry. REGN outperforms 95.93% of its industry peers.
The Average Return On Invested Capital over the past 3 years for REGN is significantly above the industry average of 13.83%.
The 3 year average ROIC (19.85%) for REGN is well above the current ROIC(9.81%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.43% | ||
| ROE | 15.87% | ||
| ROIC | 9.81% |
ROA(3y)19.52%
ROA(5y)18.66%
ROE(3y)25.8%
ROE(5y)25.67%
ROIC(3y)19.85%
ROIC(5y)18.57%
1.3 Margins
REGN's Profit Margin of 33.61% is amongst the best of the industry. REGN outperforms 98.41% of its industry peers.
REGN's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 30.28%, REGN belongs to the best of the industry, outperforming 98.76% of the companies in the same industry.
REGN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 86.86%, REGN belongs to the top of the industry, outperforming 90.44% of the companies in the same industry.
In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.28% | ||
| PM (TTM) | 33.61% | ||
| GM | 86.86% |
OM growth 3Y-7.75%
OM growth 5Y-2.63%
PM growth 3Y-10%
PM growth 5Y-3.71%
GM growth 3Y0.05%
GM growth 5Y-1.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), REGN is creating value.
REGN has less shares outstanding than it did 1 year ago.
REGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
REGN has an Altman-Z score of 7.93. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
REGN's Altman-Z score of 7.93 is amongst the best of the industry. REGN outperforms 85.49% of its industry peers.
REGN has a debt to FCF ratio of 0.81. This is a very positive value and a sign of high solvency as it would only need 0.81 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.81, REGN belongs to the best of the industry, outperforming 96.11% of the companies in the same industry.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
REGN has a worse Debt to Equity ratio (0.09) than 66.02% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.81 | ||
| Altman-Z | 7.93 |
ROIC/WACC0.89
WACC10.98%
2.3 Liquidity
A Current Ratio of 5.28 indicates that REGN has no problem at all paying its short term obligations.
With a Current ratio value of 5.28, REGN perfoms like the industry average, outperforming 56.11% of the companies in the same industry.
REGN has a Quick Ratio of 4.46. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio (4.46) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.28 | ||
| Quick Ratio | 4.46 |
3. Growth
3.1 Past
REGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.14%.
Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.91% on average per year.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 5.72% in the last year.
REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.34% yearly.
EPS 1Y (TTM)2.14%
EPS 3Y11.42%
EPS 5Y13.91%
EPS Q2Q%7.51%
Revenue 1Y (TTM)5.72%
Revenue growth 3Y15.57%
Revenue growth 5Y14.34%
Sales Q2Q%10.65%
3.2 Future
REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.46% yearly.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 7.41% on average per year.
EPS Next Y4.74%
EPS Next 2Y2.43%
EPS Next 3Y5.68%
EPS Next 5Y8.46%
Revenue Next Year9.68%
Revenue Next 2Y6.96%
Revenue Next 3Y6.85%
Revenue Next 5Y7.41%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.14, which indicates a correct valuation of REGN.
Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 96.64% of the companies listed in the same industry.
REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 28.29, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 14.97, which indicates a correct valuation of REGN.
REGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 95.93% of the companies in the same industry.
REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.14 | ||
| Fwd PE | 14.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 96.99% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 96.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.77 | ||
| EV/EBITDA | 12.87 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REGN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)3.19
PEG (5Y)1.09
EPS Next 2Y2.43%
EPS Next 3Y5.68%
5. Dividend
5.1 Amount
REGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REGENERON PHARMACEUTICALS
NASDAQ:REGN (1/21/2025, 6:15:54 PM)
After market: 687.8 0 (0%)687.8
+6.22 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.84%
Inst Owner Change-1%
Ins Owners1.55%
Ins Owner Change0.14%
Market Cap75.58B
Analysts78.82
Price Target1093.96 (59.05%)
Short Float %1.97%
Short Ratio2.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.63%
Min EPS beat(2)4.48%
Max EPS beat(2)6.79%
EPS beat(4)3
Avg EPS beat(4)3.1%
Min EPS beat(4)-7.23%
Max EPS beat(4)8.36%
EPS beat(8)7
Avg EPS beat(8)5.83%
EPS beat(12)10
Avg EPS beat(12)6.17%
EPS beat(16)14
Avg EPS beat(16)11.05%
Revenue beat(2)1
Avg Revenue beat(2)1.16%
Min Revenue beat(2)-0.62%
Max Revenue beat(2)2.93%
Revenue beat(4)2
Avg Revenue beat(4)0.14%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.93%
Revenue beat(8)6
Avg Revenue beat(8)1.95%
Revenue beat(12)10
Avg Revenue beat(12)2.54%
Revenue beat(16)12
Avg Revenue beat(16)4.66%
PT rev (1m)-1.27%
PT rev (3m)-8.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.14 | ||
| Fwd PE | 14.97 | ||
| P/S | 5.46 | ||
| P/FCF | 22.77 | ||
| P/OCF | 17.79 | ||
| P/B | 2.58 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | 12.87 |
EPS(TTM)45.43
EY6.61%
EPS(NY)45.94
Fwd EY6.68%
FCF(TTM)30.21
FCFY4.39%
OCF(TTM)38.65
OCFY5.62%
SpS126.01
BVpS266.87
TBVpS256.67
PEG (NY)3.19
PEG (5Y)1.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.43% | ||
| ROE | 15.87% | ||
| ROCE | 12.41% | ||
| ROIC | 9.81% | ||
| ROICexc | 13.81% | ||
| ROICexgc | 14.49% | ||
| OM | 30.28% | ||
| PM (TTM) | 33.61% | ||
| GM | 86.86% | ||
| FCFM | 23.97% |
ROA(3y)19.52%
ROA(5y)18.66%
ROE(3y)25.8%
ROE(5y)25.67%
ROIC(3y)19.85%
ROIC(5y)18.57%
ROICexc(3y)43.62%
ROICexc(5y)35.04%
ROICexgc(3y)49.24%
ROICexgc(5y)38.42%
ROCE(3y)25.13%
ROCE(5y)23.5%
ROICexcg growth 3Y45.71%
ROICexcg growth 5Y24.6%
ROICexc growth 3Y35.5%
ROICexc growth 5Y19.28%
OM growth 3Y-7.75%
OM growth 5Y-2.63%
PM growth 3Y-10%
PM growth 5Y-3.71%
GM growth 3Y0.05%
GM growth 5Y-1.45%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.81 | ||
| Debt/EBITDA | 0.58 | ||
| Cap/Depr | 197.68% | ||
| Cap/Sales | 6.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.1% | ||
| Profit Quality | 71.31% | ||
| Current Ratio | 5.28 | ||
| Quick Ratio | 4.46 | ||
| Altman-Z | 7.93 |
F-Score7
WACC10.98%
ROIC/WACC0.89
Cap/Depr(3y)295.5%
Cap/Depr(5y)270.26%
Cap/Sales(3y)7.93%
Cap/Sales(5y)7.3%
Profit Quality(3y)83.99%
Profit Quality(5y)80.7%
High Growth Momentum
Growth
EPS 1Y (TTM)2.14%
EPS 3Y11.42%
EPS 5Y13.91%
EPS Q2Q%7.51%
EPS Next Y4.74%
EPS Next 2Y2.43%
EPS Next 3Y5.68%
EPS Next 5Y8.46%
Revenue 1Y (TTM)5.72%
Revenue growth 3Y15.57%
Revenue growth 5Y14.34%
Sales Q2Q%10.65%
Revenue Next Year9.68%
Revenue Next 2Y6.96%
Revenue Next 3Y6.85%
Revenue Next 5Y7.41%
EBIT growth 1Y-4.86%
EBIT growth 3Y6.62%
EBIT growth 5Y11.34%
EBIT Next Year8.14%
EBIT Next 3Y6.97%
EBIT Next 5Y9.29%
FCF growth 1Y-19.98%
FCF growth 3Y22.33%
FCF growth 5Y15.14%
OCF growth 1Y-25.06%
OCF growth 3Y20.62%
OCF growth 5Y15.92%